Eton Pharmaceuticals Inc — Quarterly Cash Flow (NASDAQ:ETON) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics Dividends

Quarterly Annual

Total assets 35.84 M76.12 M84.03 M101.68 M104.51 M Total liabilities 19.86 M51.7 M59.58 M77.72 M81.38 M Total equity 15.98 M24.43 M24.45 M23.96 M23.13 M Total liabilities & shareholders' equities 35.84 M76.12 M84.03 M101.68 M104.51 M Total debt ————— Net debt —————

Notizie

La soluzione orale DESMODA riceve l’approvazione FDA per il diabete insipido

DESMODA oral solution receives FDA approval for diabetes insipidus

Il titolo di Eton Pharmaceuticals sale dopo la licenza di un farmaco per malattie ultra-rare

Eton Pharmaceuticals stock rises after licensing ultra-rare disease drug

Eton Pharmaceuticals licenses ultra-rare disease treatment candidate

Implied Volatility Surging for Eton Pharmaceuticals Stock Options

Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Beats Revenue Estimates

Gli EPS di Eton Pharmaceuticals hanno mancato le aspettative per 0,07$, il fatturato supera le previsioni

Eton Pharmaceuticals earnings missed by $0.07, revenue topped estimates

Airbnb, Monster Beverage, Take-Two and more set to report earnings Thursday

Eton Stock Has Focused Growth But Valuation Limits Upside: Why I Choose To Hold

Monopar Therapeutics: A Healthy Dose Of Skepticism Warranted (NASDAQ:MNPR)